{"id":"NCT01057810","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer","officialTitle":"Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2015-04","completion":"2015-07","firstPosted":"2010-01-27","resultsPosted":"2016-08-18","lastUpdate":"2016-08-18"},"enrollment":837,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Ipilimumab","otherNames":["BMS-734016","MDX010"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ipilimumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo","primaryOutcome":{"measure":"Overall Survival (OS) Time","timeFrame":"Randomization until death from any cause, up to April 2015, approximately 57 months","effectByArm":[{"arm":"Placebo","deltaMin":29.73,"sd":null},{"arm":"Ipilimumab","deltaMin":28.65,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3667"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":134,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Mexico","Netherlands","Norway","Poland","Puerto Rico","Romania","Spain","Sweden","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["24722180","21917607"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":199},"commonTop":["Diarrhoea","Fatigue","Rash","Nausea","Decreased appetite"]}}